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Large quantities of low-value protein rich co-products, such as salmon skin and trimmings, are 
generated annually. These co-products can be upgraded to high-value functional ingredients. The 
aim of this study was to assess the antidiabetic potential of salmon skin gelatin and trimming-
derived protein hydrolysates in vitro. The gelatin hydrolysate generated with Alcalase 2.4L and 
Flavourzyme 500L exhibited significantly higher (p<0.001)  insulin and GLP-1 secretory activity 
from pancreatic BRIN-BD11 and enteroendocrine GLUTag cells, respectively, when tested at 2.5 
mg/mL compared to hydrolysates generated with Alcalase 2.4L or Promod 144MG. The gelatin 
hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L showed significantly more 
potent (p<0.01) DPP-IV inhibitory activity than those generated with Alcalase 2.4L or Promod 
144MG. No significant difference was observed in the insulinotropic activity mediated by any of 
the trimming-derived hydrolysates when tested at 2.5 mg/mL. However, the trimmings 
hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L exhibited significantly higher 
DPP-IV inhibitory (p<0.05:Alcalase 2.4L and p<0.01:Promod 144MG) and GLP-1 (p<0.001, 2.5 
mg/mL) secretory activity than those generated with Alcalase 2.4L or Promod 144MG. The 
salmon trimmings hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L when 
subjected to simulated gastrointestinal digestion (SGID) was shown to retain its GLP-1 secretory 
and DPP-IV inhibitory activities, in addition to improving its insulin secretory activity. However, 
the gelatin hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L was shown to lose 
GLP-1 secretory activity following SGID. A significant increase in membrane potential (p<0.001) 
and intracellular calcium (p<0.001) by both co-product hydrolysates generated with Alcalase 2.4L 
and Flavourzyme 500L suggest that both hydrolysates mediate their insulinotropic activity 
through the KATP channel-dependent pathway. Additionally, by stimulating a significant increase 














mediate insulin secretion through the protein kinase A pathway. The results presented herein 
demonstrate that salmon co-product hydrolysates exhibit promising in vitro antidiabetic activity. 
 




In response to the increased global demand for seafood, food production from fisheries and 
aquaculture exceeded 160 million tons in 2014 (FAO, 2016). With the world population due to 
reach 9.8 billion by 2050, the demand for such food products is set to increase further (UN, 2017). 
At present only 50–60% of total marine landings are utilized for direct human consumption with 
the remainder used as fertiliser or for animal and farmed fish/shellfish feed (Norris, Harnedy, & 
FitzGerald, 2013). With the projected escalation in seafood production and the fact that a 
significant quantity of the co-product material generated during fish/shellfish processing, if 
handled and stored correctly, is suitable for human consumption, co-products from marine food 
processing are potential added-value components capable of ensuring a sustainable food supply. 
Low-value co-products such as salmon trimmings and skin, which are generated during the 
salmon filleting process, contain significant quantities of high quality protein and gelatin.  
Gelatin, a partially hydrolysed form of the triple helix protein collagen, is widely used in the food, 
pharmaceutical and cosmetics industries because of its unique functional and technological 
properties (Gómez-Guillén, Giménez, López-Caballero, & Montero, 2011). The most abundant 
current sources of commercial gelatin arise from terrestrial animal by-products such as porcine 
and bovine skin/hide and bones (Gómez-Guillén et al., 2011).  However, the food, pharmaceutical 
and cosmetic industries are now searching for alternative sources of gelatin and gelatin derivatives 














be utilised by certain religious groups (e.g., Halal and Kosher certified) and customers who have 
made specific lifestyle choices in relation to diet (e.g., vegetarians and vegans).   
In addition to acting as potential sustainable food sources to meet future demand, marine proteins 
contain a large range of bioactive components in the form of peptides encrypted within their 
primary sequences.  Evidence indicates that novel proteins and peptides from the marine 
environment can have a favourable impact on health enhancement and may be utilised to combat 
the ever-increasing incidences of non-communicable diseases such as cardiovascular disease, 
cancer, chronic respiratory disease and diabetes (Harnedy & FitzGerald, 2012).  
T2DM is a chronic progressive metabolic disorder that is characterised by hyperglycaemia due to 
impaired insulin secretion and tissue insulin resistance. In the early stages of T2DM elevated 
pancreatic insulin secretion (hyperinsulinaemia) can compensate for tissue insulin resistance thus 
avoiding hyperglycaemia.  Insulin resistance is characterised by impaired responsiveness of cells 
in the muscles, liver and fat tissue towards insulin, which leads to a reduction in glucose uptake 
and hyperglycaemia, when pancreatic insulin production can no longer compensate (Goldstein, 
2002). Approximately 415 million individuals worldwide are currently living with the disorder 
with approximately 12% ($673 billion) of global healthcare expenditure spent on diabetes 
management/treatment (IDF Atlas, 2015). This is expected to increase to 642 million people by 
2040 if immediate interventions are not made (IDF Atlas, 2015). Drug therapies such as 
biguanides, meglitinides, sulphonylureas, thiazolidinediones, insulin, insulin analogues, sodium 
glucose co-transporter-2 (SGLT-2) inhibitors, incretin-based therapies, DPP-IV and α-glucosidase 
inhibitors are currently used for treatment of T2DM (Olokoba, Obateru, & Olokoba, 2012).  These 
therapies are expensive and often display adverse side effects. Therefore, there is an ever-
increasing need to identify natural functional components for the management of this metabolic 
disorder. Evidence-based research has shown that blood glucose levels in humans can be 














direct and/or indirect mechanisms (Oseguera-Toledo, de Mejía, Reynoso-Camacho, Cardador-
Martínez, & Amaya-Llano, 2014; Promintzer & Krebs, 2006). These mechanisms include direct 
stimulation of insulin secretion from pancreatic β-cells or indirectly through the release of the gut 
incretin hormone GLP-1 (Oseguera-Toledo et al., 2014; Promintzer & Krebs, 2006). The 
insulinotropic potency of protein and protein hydrolysates can differ significantly depending on 
the primary sequence of the peptides and amino acids generated during digestion (McGregor & 
Poppitt, 2013; Ranawana & Kaur, 2013). 
Salmon protein hydrolysates/peptides exhibit antidiabetic activity in vitro and in vivo. In previous 
studies we have shown that muscle protein and gelatin hydrolysates derived from Atlantic salmon 
trimmings inhibit dipeptidyl peptidase-IV (DPP-IV) in vitro (Neves, Harnedy, O’Keeffe, Alashi, 
et al., 2017; Neves, Harnedy, O’Keeffe, & FitzGerald, 2017). This was also seen with 
hydrolysates generated from salmon muscle protein and salmon skin derived gelatin (Falkenberg, 
Stagsted, & Nielsen, 2014; Li-Chan, Hunag, Jao, Ho, & Hsu, 2012).  Salmon protein hydrolysates 
were shown to stimulate insulin-induced glucose uptake in L6 myocytes (Jin, 2012). Salmon skin 
gelatin derived peptides were reported to reduce blood glucose concentrations in diabetic rat 
models through enhancement of circulating GLP-1 concentration and reduction in T2DM-related 
islet cell apoptosis (Hsieh, Wang, Hung, M.C., & Hsu, 2012; Zhu et al., 2017; Zhu, Peng, Liu, 
Zhang, & Li, 2010).  Salmon protein incorporation into a high-fat, high-sucrose diet was shown to 
improve whole-body insulin sensitivity and glucose tolerance in male Wistar rats (Pilon et al., 
2011). In addition,  low molecular weight peptides from a salmon protein hydrolysate were 




 mice (Chevrier et 
al., 2015). Furthermore, marine collagen peptides have been shown to beneficially modulate 
glucose metabolism in T2DM human subjects (Zhu, Li, et al., 2010a; Zhu, Li, et al., 2010b). 
These individuals showed lower fasting blood glucose and glycated haemoglobin (HbA1c) 














ingestion of marine collagen peptides. Furthermore, we have recently shown that a blue whiting 
(Micromesistius poutassou) muscle protein hydrolysate exhibited antidiabetic activity in vitro and 
in normal healthy mice (Harnedy et al., 2018). 
The objective of this study was to employ in vitro analysis to investigate the antidiabetic potential 
of salmon co-product hydrolysates and to determine the mechanism by which the hydrolysates 
may mediate their antidiabetic activity.  
 
2. Materials and Methods  
2.1. Materials and chemicals 
Abz-Gly-p-nitro-Phe-Pro-OH, Abz-Gly-OH-HCl, H-Gly-Pro-AMC (7-amino-4–methyl coumarin) 
and Diprotin A were obtained from Bachem Feinchemikalien (Bubendorf, Switzerland). Promod 
144MG was kindly provided by Biocatalysts Ltd. (Cardiff, Wales, UK). HPLC grade water and 
acetonitrile were from VWR International (Dublin, Ireland) and trinitrobenzenesulphonic acid 
(TNBS) reagent was from Medical Supply Co Ltd. (Dublin, Ireland). Calcium chloride dihydrate 
(CaCl2×2H2O), D-glucose, HEPES, hydrochloric acid (HCl), magnesium sulphate 
(MgSO4×7H2O), potassium dihydrogen orthophosphate (KH2PO4), potassium chloride (KCl), 
sodium bicarbonate (NaHCO3) and sodium chloride (NaCl) were purchased from BDH Chemicals 
Ltd (Poole, Dorset, UK).  Fetal bovine serum (FBS), Hank’s buffered saline solution (HBSS 10× 
stock), penicillin-streptomycin (0.1 g/L), RPMI-1640 culture media, Dulbecco’s modified Eagle’s 
medium (DMEM) containing high glucose and trypsin/EDTA (10×) were obtained from Gibco 
Life Technologies Ltd (Paisley, Strathclyde, UK).  Radio-labelled sodium iodide (Na
125
I, IMS 100 
mCi/mL stock) was purchased from Perkin Elmer (Buckinghamshire, UK). Rat insulin standard 
was purchased from Novo Industria, Copenhagen, Denmark. All other reagents including DPP-IV, 
from porcine kidney (≥10 units/mg protein), Alcalase
®
 2.4L and Flavourzyme
®
 500L were 














Company Ltd., Carrigaline, Co. Cork, Ireland, kindly provided samples of Atlantic salmon (Salmo 
salar) trimmings and skin. 
 
2.2 Extraction and quantification of gelatin from salmon skin 
Salmon skin which were stored at -20°C were thawed at room temperature cut into pieces (about 
5×5 cm) and were then washed by stirring in distilled water (1:5 (w/v)) for 15 min. The skins were 
soaked in 0.2 M NaOH (1:5 (w/v)) and stirred at room temperature for 15 min to remove non-
collagenous proteins. This procedure was repeated three times. The skins were separated by 
filtration using a double layer of cheesecloth between each step of the extraction procedure. The 
NaOH was then removed by sequentially soaking (×3) the skins for 15 min in distilled water at a 
mass:volume ratio of 1:5 (w/v) until the pH was neutral. The skins were suspended in distilled 
water (1:6 (w/v)); the pH was adjusted to pH 3.0 with 1N HCl, and stirred for 1 h at room 
temperature. The HCl was removed by sequentially soaking (×3) the skins for 15 min in distilled 
water (1:5 (w/v)) until the pH was neutral. The gelatin in the swollen skins was then extracted in 
distilled water 1:5 (w/v) during heating at 50°C for 16 h. The gelatin-containing supernatant was 
freeze-dried and stored at -20
o
C until required. The protein content of the gelatine isolate and 
salmon trimmings  protein hydrolysate was determined by the macro-Kjeldahl procedure as 
described previously by Connolly, Piggott, and FitzGerald (2013) using a nitrogen to protein 
conversion factor of 5.55  and 6.25, respectively (FAO/INFOODS, 2012; Kristinsson & Rasco, 
2000). 
 
2.3 Enzymatic hydrolysis of salmon skin gelatin and trimmings 
A 7% (w/v) gelatin solution (on a protein basis) was preheated to 50°C and adjusted to pH 7.0 and 
hydrolysed with Alcalase 2.4L, Alcalase 2.4L and Flavourzyme 500L, and Promod 144MG at an 














maintained at pH 7.0 using a pH-stat (842 Titrando, Metrohm, Switzerland) and enzyme activity 
was terminated after 4 h incubation by heating at 90
o
C for 20 min. Salmon trimming proteins were 
hydrolysed by direct hydrolysis. The minced salmon trimmings were suspended at 1:1.75 (w/v) in 
distilled water and homogenised at room temperature at 24,000 rpm over 4 × 15 sec treatments 
(Ultra-Turrax® T25 Basic, IKA®, Staufen, Germany). Additional water was added following 
homogenisation to obtain a 6.83% (w/v) protein suspension. Hydrolysis was performed as 
described above and the peptides generated were separated by 2× filtration (Whatman grade 1: 11 




2.4 In vitro insulin secretion in BRIN-BD11 cells 
The effect of the hydrolysates on in vitro insulin secretion was measured using clonal pancreatic 
BRIN-BD11 cells as previously described (McClenaghan et al., 1996). Briefly, cells were seeded 
(150,000 cells per well) into 24-well plates and allowed to attach overnight at 37°C. After a 40 
min pre-incubation (1.1 mM glucose; 37°C) cells were incubated (20 min; 37°C) in the presence 
of 5.6 mM glucose with a range of hydrolysate concentrations (0.039–2.500 mg/mL). Following 
20 min incubation, sample were removed from each well and aliquots (200 μL) stored at -20°C 
prior to measurement of insulin by radioimmunoassay (RIA) as described previously (Flatt & 
Bailey, 1981).  
In order to determine if the hydrolysate samples were cytotoxic, the lactate dehydrogenase (LDH) 
concentrations in cellular supernatants were measured using a CytoTox96 non-radioactive 
cytotoxicity assay kit according to the manufacturers’ protocol (Promega, Madison, WI, USA). 
The release of cytoplasmic LDH from cells treated with the hydrolysates indicates that the 
integrity of the plasma membrane has been compromised (Owolabi et al., 2016). 
 














In vitro DPP-IV inhibitory activity of the hydrolysates was determined as described by Harnedy, 
O’Keeffe, and FitzGerald (2015).  The results were expressed as IC50 values (concentration that 
inhibits DPP-IV activity by 50%, n=3). Diprotin A (Pro-Ile-Pro) was used as a positive control.  
 
2.6 Determination of GLP-1 secretion from GLUTag cells  
The GLP-1 secretory effects of hydrolysates were measured in vitro using a murine GLUTag cell 
line as described previously (Ojo, Conlon, Flatt, & Abdel-Wahab, 2013). In brief, cells were 
seeded on matrigel coated plates (150,000 cells/well) and incubated overnight at 37°C. Following 
a 40 min pre-incubation step (37°C), cells were treated with the hydrolysates (2.5 mg/mL) 
prepared in 2 mM glucose and incubated for 2 h at 37°C. Following incubation, the supernatant 
buffer was removed and stored at -20°C prior to measurement of total GLP-1 concentration using 
a sandwich ELISA kit according to the manufacturer’s protocol (GLP-1 Total ELISA, EZGLP-
1T-36K, Millipore, MA, USA). 
 
2.7   Membrane potential, intracellular calcium ([Ca
2+
]i) and cAMP production 
Changes in membrane potential and [Ca
2+
]i were assessed fluorimetrically utilizing monolayers of 
BRIN-BD11 cells as described previously (Srinivasan, Mechkarska, Abdel-Wahab, Flatt, & 
Conlon, 2013) using a membrane potential assay kit or a Ca
2+
 assay kit (Molecular Devices, 
Sunnyvale, CA, USA) according to the manufacturer's  protocols.  In brief, cells were incubated at 
37°C for 10 min with the hydrolysates generated using Alcalase 2.4L and Flavourzyme 500L (2.5 
mg/mL). Control incubations with 10 mM KCl and 10 mM alanine in the presence of 5.6 mM 
glucose were also performed. Data were acquired using a FlexStation scanning fluorimeter with an 
integrated fluid transfer workstation (Molecular Devices, Rockville, MD, USA). The effect of the 
hydrolysate on the production of cAMP was also assessed in BRIN-BD11 cells. Cells were seeded 














HBSS buffer before incubation with the sample (2.5 mg/mL) in the presence of 200 μM 
of isobutyl-l-methylxanthine (IBMX) for 20 min at 37°C. After incubation, media was removed 
and cells lysed before measurement using a cAMP detection kit (R&D Systems Parameter, 
Abingdon, UK; Hogan et al., 2011). 
 
2.8 Physicochemical characterisation  
The degree of hydrolysis (DH) was estimated using a modification of the TNBS method described 
by Spellman, McEvoy, O'Cuinn, and FitzGerald (2003) as reported in Harnedy and FitzGerald 
(2013). All samples were analysed in triplicate (n=3). DH was calculated as follows: DH = 100 × 
((AN2-AN1)/Npb). Where AN1 is the amino nitrogen content of the unhydrolysed protein (mg/g 
protein). An AN1 value of of 5.6 mg amino nitrogen/g protein was used for determination of the 
% DH of salmon trimming proteins. This value was as recommended by Adler-Nissen (1979) 
when the source protein value is not known. AN2 is the amino nitrogen content of the hydrolysate 
(mg/g protein) and Npb is the nitrogen content of the peptide bonds in the protein substrate which 
was 102.3 and 155.5 for fish muscle and gelatin, respectively (Adler-Nissen, 1979). Molecular 
mass distribution profiles of hydrolysates were determined using gel permeation-high performance 
liquid chromatography (GP-HPLC) by the method described by Spellman, Kenny, O'Cuinn, and 
FitzGerald (2005). Reverse-phase ultra-performance liquid chromatography (RP-UPLC) was 
performed as described previously by Nongonierma and FitzGerald (2012) using MS grade water 
and ACN and a flow rate of 0.2 mL/min.  
 
2.9 Total and free amino acid content 
Total and free amino acid analysis of salmon co-product hydrolysates generated with Alcalase 














Research Centre, Moorepark, Fermoy, Co. Cork, Ireland using methods previously  described 
(Hill, 1965; McDermott et al., 2016).  
 
2.10 Peptide identification 
The peptides in the salmon co-product hydrolysate generated using Alcalase 2.4L and 
Flavourzyme 500L were separated and identified by UPLC-ESI-MS/MS with the use of an 
ACQUITY UPLC (Waters, Milford, MA, USA) connected to an Impact HD Ultra high resolution 
(UHR) Q-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany). An aliquot (7 l) of the 
hydrolysate (0.1 mg/mL in mobile phase A (0.1% (v/v) formic acid (FA) in MS-grade H2O) was 
injected onto an Acquity BEH 300 C18 column (2.1×50 mm, 1.7 µm; Waters, Dublin, Ireland) 
and separated as follows where mobile phase B was 0.1% (v/v) formic acid in 80% ACN (v/v): 0–
0.28 min: 0% B; 0.28-45 min: 0-80% B; 45-46 min: 80-100% B; 46-48 min 100% B; 48-49 min: 
100-50% B; 49-50 min 50% B; 50-51 min 50-0% B; 51-53 min 0% B at a flow rate of 0.2 
mL/min. Peptide identification was performed using the MS/MS methods in positive ion mode as 
previously described (O'Keeffe & FitzGerald, 2015; O'Keeffe, Norris, Alashi, Aluko, & 
FitzGerald, 2017). Mobile phase A was 0.1 % (v/v) FA in MS grade H2O. Peptides were identified 
by searching the MS/MS spectra against a database (Chordata limited SwissProt) and by de novo 
sequencing. Peptides ≥ 6 amino acids in length identified by de novo sequencing were searched 
for homology within fish proteins using the FASTAM tool (available at 
http://www.ebi.ac.uk/Tools/sss/fastm/). Short peptide sequences (≤5 amino acids) in the salmon 
skin gelatin hydrolysate were searched for homology with collagen proteins using an ‘in-house’ 
database consisting of the reviewed protein sequences of 288 collagen proteins from the phylum 
Chordata. Short peptide sequences (≤5 amino acids) in the salmon trimmings-derived hydrolysate 














database consisting of the reviewed protein sequences of 158 proteins from the phylum Salmo 
salar.  
 
2.11 Simulated gastrointestinal digestion (SGID)  
SGID was performed by the method as described by Walsh et al. (2004) with modifications. In 
brief, a 2.0% (w/v) hydrolysate on a protein basis was incubated with pepsin at an E:S of 2.5% 
(w/w) at 37 °C and pH 2.0 for 90 min. Following adjustment to pH 7.0 and heat treatment at 90°C 
for 20 min the sample was incubated at 37 °C with Corolase PP (E:S of 1% (w/w)). After 150 min 
the sample was heat treated as described above. All samples were subsequently freeze-dried and 
stored at -20 °C. 
 
2.12 Statistical analysis 
SPSS (version 20, IBM Inc., Chicago, IL, USA) was utilized to perform statistical analysis on the 
degree of hydrolysis and DPP-IV inhibition data. Statistical significance at a level of p<0.05 was 
determined using one-way analysis of variance (ANOVA) followed by Tukey’s and Games–
Howell post-hoc tests, where applicable. All other results were analysed using GraphPad Prism 
version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Statistical analyses were performed 
using the Students unpaired t-test. Where appropriate, data were compared using one-way and 
two-way analysis of variance (ANOVA), followed by Student-Newman-Keuls post hoc test. 
Incremental area under the curve (AUC) for plasma glucose and insulin were calculated using 
GraphPad Prism. Groups of data were considered to be significantly different if p<0.05. All data is 
presented as mean ± S.E.M. 
 
3. Results & Discussion 














The insulin secretory activity mediated by salmon co-product hydrolysates was determined 
between 0.039 and 2.5 mg/mL. Cell cytotoxicity analysis (LDH assay) performed at each of the 
sample concentrations (0.039-2.5 mg/mL) tested indicate that the insulinotropic activity observed 
was due to the action of the hydrolysate and not due to cell death (data not shown). The salmon 
skin gelatin hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L induced a 
significantly higher insulinotropic response from BRIN-BD11 cells at concentrations ranging from 
0.625 to 2.500 mg/mL compared to the glucose control (p<0.001-0.05, Fig. 1). A 3.2-fold increase 
in insulin secretion above the basal rate (5.6 mM glucose alone) was observed following 
incubation with 2.5 mg/mL of the gelatin hydrolysate generated with Alcalase 2.4L and 
Flavourzyme 500L. Salmon skin gelatin hydrolysates generated with Alcalase 2.4L or Promod 
144MG were shown to mediate an insulin stimulatory response similar to the glucose control at 
each of the concentrations tested (Fig. 1).  In contrast, all salmon trimming-derived hydrolysates 
were shown to induce a significantly higher (p<0.001-0.05) insulinotropic response when tested at 
2.5 mg/mL compared to the glucose control. No significant difference was observed in the 
concentration of insulin released from pancreatic cells when all salmon trimming hydrolysates 
were tested at 2.5 mg/mL (Fig. 1). To the best of our knowledge, this is the first report showing 
the direct action of salmon-derived hydrolysates on insulin secretion from BRIN-BD11 cells. The 
insulin secretory activity observed with the salmon gelatin and trimming hydrolysates generated 
with Alcalase 2.4L and Flavourzyme 500L, which showed a 3.2- and 3.0-fold increase, 
respectively, relative to the glucose control when tested at 2.5 mg/mL. This was in the same order 
(3.8-fold) as the increase seen with a blue whiting hydrolysate generated with the same enzymes 
(Harnedy et al., 2018). 
Differences in the RP-UPLC (Supplementary Fig. S1) and the molecular mass distribution profiles 
(Table 1) for each of the gelatin hydrolysates demonstrate that different peptides were generated 














size and sequence of the peptides had a significant effect on the insulinotropic potency of the 
hydrolysate. However, this was not observed with the salmon trimming derived hydrolysates 
where the differences in the DH, abundance of peptides < 1 kDa and RP-UPLC profiles had no 
effect on insulin secretory activity (Table 1 and Supplementary Fig. S1).  
 
3.2. Effect of salmon-derived hydrolysates on GLP-1 release from GLUTag cells and DPP-IV 
inhibition in-vitro 
The incretin hormone, GLP-1 released from the enteroendocrine L-cells of the intestine, stimulates 
the release of insulin from β-cells through distinct G-protein-coupled receptors highly expressed 
on the cells (Mignone, Wu, Horowitz, & Rayner, 2015). GLP-1 is rapidly degraded by DPP-IV, an 
ubiquitous enzyme expressed on the surface of most cell types (Green, Gault, O'Harte, & Flatt, 
2004). Different strategies have been explored to aid glycaemic management in T2DM including 
the development of long acting GLP-1 analogues (incretin mimetics) and/or increasing the half-
life of GLP-1 through the development of specific DPP-IV inhibitors. However, new treatments 
that could beneficially modulate endogenous enteroendocrine cell secretory mechanisms and 
increase GLP-1 release are currently being researched (Wang, Liu, Chen, Li, & Qu, 2015). 
As shown in Fig. 2 the hydrolysates generated from both salmon co-products with Alcalase 2.4L 
and Flavourzyme 500L showed significantly higher GLP-1 secretory potential (p<0.001), than 
those generated with Alcalase 2.4L or Promod 144MG. The hydrolysate generated from skin-
derived gelatin and trimming muscle proteins demonstrated a 3.8- and 2.4-fold (p<0.001) increase 
in GLP-1 secretion above the basal level, respectively (Fig. 2). This was higher than that observed 
with a blue whiting protein hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L that 
showed a 1.4- fold increase in GLP-1 secretion above the basal level when tested at the same 
concentration (2.5mg/mL; Harnedy et al., 2018). For both co-products the hydrolysates generated 














similar (trimming protein: 1.1-fold increase) to the glucose control whereas the hydrolysates 
generated with Promod 144MG elicited a response lower than the glucose control. Whilst a 
salmon skin gelatin hydrolysate has previously been reported to enhance circulating GLP-1 
concentrations in vivo through increased DPP-IV inhibition (Hsieh et al., 2012), to our knowledge 
this is the first report of the direct action of salmon gelatin and muscle protein hydrolysates on 
GLP-1 release from enteroendocrine GLUTag cells. 
In comparison, the gelatin hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L, 
when tested at 2.5 mg/ml, mediated both a significantly higher insulin and GLP-1 secretory 
response than those mediated by gelatin hydrolysates generated with Alcalase 2.4L and Promod 
144MG (Fig. 1 & 2). However, while the salmon trimmings hydrolysate generated with Alcalase 
2.4L and Flavourzyme 500L and  tested at 2.5 mg/ml, was more potent at mediating the release of 
GLP-1 compared to the other salmon trimmings hydrolysates, no significant difference was 
observed in the  amount of insulin released from pancreatic cells when all salmon trimming 
hydrolysates were tested at 2.5 mg/mL (Fig. 1 & 2).  
The salmon co-product hydrolysates generated with Alcalase 2.4L and Flavourzyme 500L herein 
were also shown to be more potent (p<0.05) inhibitors of DPP-IV activity in vitro than those 
hydrolysates generated with Alcalase 2.4L and Promod 144MG (Table 1). In our previous study, a 
similar trend was observed where gelatin and protein hydrolysates generated with Alcalase 2.4L 
and Flavourzyme 500L from salmon trimmings had more potent DPP-IV inhibitory activity than 
those generated with Alcalase 2.4L and Promod 144MG (Neves, Harnedy, O’Keeffe, Alashi, et 
al., 2017; Neves, Harnedy, O’Keeffe, & FitzGerald, 2017). However, the IC50 values obtained 
herein for hydrolysates generated from salmon skin gelatin (0.90 ± 0.05 mg/mL) and trimmings 
derived proteins (0.84 ± 0.04 mg/mL), with Alcalase 2.4L and Flavourzyme 500L, were 
significantly higher than values obtained previously for salmon trimmings derived gelatin (0.55 














Harnedy, O’Keeffe, Alashi, et al., 2017; Neves, Harnedy, O’Keeffe, & FitzGerald, 2017). This 
difference in DPP-IV inhibitory response may be due to the source of the gelatin isolate and the 
method used to generate the muscle protein hydrolysates. In the previous study, the gelatin was 
isolated from salmon trimmings that contained both muscle and skin derived gelatin, whereas in 
the present study the gelatin was derived solely from the skin. It may be possible that salmon 
muscle derived gelatin contains peptide sequences with more potent DPP-IV inhibitory activity 
than that derived from skin. In the present study, salmon protein hydrolysates were generated by 
direct hydrolysis of homogenised salmon trimmings, whereas in the previous study salmon muscle 
proteins were extracted prior to hydrolysis. Direct hydrolysis was utilised in this study as it is 
believed to be a more industrially efficient method for generation of muscle protein hydrolysates 
and to be a process which maybe more easily transferred to semi-pilot or pilot scale. While the 
DPP-IV inhibition results presented herein were less potent than the results reported previously 
they were more potent than those values reported elsewhere for salmon skin gelatin hydrolysates 
generated with Alcalase 2.4 L, Flavourzyme 1000 L and Bromelain (Li-Chan et al. 2012).  
In general, DPP-IV inhibitory activity has been associated with peptides having low molecular 
masses. The fact that the degree to which the gelatin and trimming muscle proteins were 
hydrolysed was higher with Alcalase 2.4L and Flavourzyme 500L and that the proportion of 
peptides <1 kDa in hydrolysates generated with these enzymes was higher than those generated 
with the other enzymes may explain the higher DPP-IV inhibitory potency of these hydrolysates 
(Table 1). Interestingly, the salmon co-product hydrolysates generated herein exhibit both DPP-IV 
inhibitory and GLP-1 secretory activity and as such may indirectly aid in improving glucose 
homeostasis in TD2M patients by increasing the concentrations of biological active GLP-1 (GLP-














Overall the salmon trimming and gelatin hydrolysates generated with Alcalase 2.4L and 
Flavourzyme 500L showed the most promising in vitro antidiabetic activity and warrants further 
investigation. 
 
3.3. Effect of salmon co-product hydrolysates on intracellular Ca
2+
 and cAMP concentration 
in BRIN-BD11 cells 
The two main signalling pathways that regulate insulin secretion from β-cells are the KATP 
channel-dependent and KATP channel-independent pathways (Henquin, 2000). In the KATP 
channel-dependent pathway, secretion of insulin is mediated by an increased [ATP]/[ADP] ratio, 
closure of ATP-sensitive potassium channels and opening of voltage-dependent calcium channels. 
This leads to calcium influx and elevated cytoplasmic intracellular calcium, inducing rapid insulin 
exocytosis. The effects of salmon co-product hydrolysates generated with Alcalase 2.4L and 
Flavourzyme 500L on membrane potential, intracellular [Ca
2+
] and cAMP concentration in BRIN-
BD11 cells were investigated to determine the potential mechanism by which these hydrolysates 
enhanced insulin secretion. 
A significant (2.9-fold) increase in membrane potential was observed with BRIN-BD11 cells 
exposed to the salmon skin gelatin hydrolysates compared to glucose alone (p<0.001, Fig. 3a).  A 
similar response was observed with the trimmings protein hydrolysates, where a 2.0-fold increase 
in membrane potential was observed (p<0.001, Fig. 3a). Both hydrolysates were shown to mediate 
a significant increase in intracellular calcium concentration compared to the glucose basal 
response, with a 14- and 17-fold increase being observed for the gelatin and trimmings 
hydrolysates, respectively (p<0.001, Fig. 3b). These increases in membrane depolarisation and 
intracellular calcium concentration would suggest that both hydrolysates mediate their 
insulinotropic activity through the KATP channel-dependent pathway. The trimmings-derived 














BD11 cells (p<0.05, data not shown). This indicates that the insulin secretory response observed 
with the trimmings-derived hydrolysate may also be via the protein kinase A (PKA) pathway 
(Doyle & Egan, 2007). In contrast, the gelatin hydrolysate did not mediate a significant increase in 
cAMP concentration in BRIN-BD11 cells (data not shown). 
 
3.4 Free amino acid composition 
Although the mechanism by which proteinaceous components exert their antidiabetic effect has 
not yet been fully elucidated, it is believed that the post prandial change in key amino acids in vivo 
is a contributing factor (Power-Grant et al., 2015). Amino acids such as Gln, Ala, Arg, Leu, Phe, 
Val, Ile, and Lys have strong insulin secretagogue activity (Dixon, Nolan, McClenaghan, Flatt, & 
Newsholme, 2003; Morifuji et al., 2010; Newsholme, Brennan, & Bender, 2006; Power-Grant et 
al., 2015). Furthermore, amino acids such as Glu, Ala, Ser and Gln, Gly, Asp, Leu and Met can 
stimulate the release of GLP-1 from intestinal cells and Phe, Arg and Tyr residues exhibit DPP-IV 
inhibitory activity (Gameiro et al., 2005; Neves, Harnedy, O’Keeffe, Alashi, et al., 2017; Neves, 
Harnedy, O’Keeffe, & FitzGerald, 2017; Reimann, Williams, da Silva Xavier, Rutter, & Gribble, 
2004).  
As shown in Table 2 both salmon co-product hydrolysates generated with Alcalase 2.4L and 
Flavourzyme 500L contain significant quantities of key insulinotropic amino acids. Two of the 
most abundant free amino acids present in the hydrolysate generated from salmon skin gelatin 
include Arg and Phe at 1.15 and 1.07 g/100g, respectively, while Phe, Leu and Arg were present at 
2.13, 1.17 and 1.01 g/100 g in the hydrolysate generated from salmon trimmings. The presence of 
these amino acids with known insulinotropic activity, in addition to other insulin secretory 
residues present at low to moderate levels (Ala, Lys, Val and Ile) may contribute to the potent 
insulinotropic activity observed with these hydrolysates. The positively charged amino acid Arg 














and trimmings hydrolysate, respectively.  This residue is believed to enhance insulin secretion 
through direct depolarization of the plasma membrane, which in turn activates voltage-dependent 
Ca
2+
 channels leading to an increase in intracellular Ca
2+
 and a subsequent stimulation of insulin 
secretion (Newsholme et al., 2006). 
The majority of the amino acids with known GLP-1 secretory activity, with the exception of Leu, 
which was present at 1.17 g/100 g in the free amino acid complement of the hydrolysate generated 
from salmon trimmings, were only found at moderate levels. However, the levels of these known 
GLP-1 secretory amino acids or the combination of such amino acids present in the hydrolysate 
may have been high enough to mediate the GLP-1 secretory response observed. Furthermore, 
residues such as Phe, Arg and Tyr, which are known to exhibit DPP-IV inhibitory activity, were 
found in high abundance in the free amino acid complement of both hydrolysates. These amino 
acids with concentrations ranging 1.07-2.13 g/100 g may contribute to the DPP-IV inhibitory 
activity observed with both hydrolysates.  
 
3.5 Total amino acids and peptide profiles 
The total amino acid composition of the salmon co-product hydrolysates generated with Alcalase 
2.4L and Flavourzyme 500L is shown in Table 2. Both co-product hydrolysates generated with 
Alcalase 2.4L and Flavourzyme 500L contain all the essential amino acids with higher quantities 
generally being found in the salmon trimming-derived hydrolysate. Trp, was not determined 
during total amino acid analysis. 
Table 2 indicates that the salmon skin gelatin hydrolysate contains a higher quantity of free Tyr 
than that determined in the hydrolysate as a whole. The reason for this is unknown; however, Tyr 
has been reported to be sensitive to destruction/modification under certain acid hydrolysis 














The most abundant amino acids found in the gelatin hydrolysate include Gly and Pro, which 
account for 27.12 and 12.76% (w/w) of the total amino acid content. This is not surprising as the 
sequence of gelatin (collagen) is composed of the repeat sequence Gly-X-Y, where X is mostly 
Pro and Y is mostly hydroxyproline. The most abundant amino acids in the trimmings-derived 
hydrolysate were Glx and Asx (Table 2).  
Although a large number of food-protein derived peptides have been shown to exhibit DPP-IV 
inhibitory activity in vitro, limited research has been performed on the identification of peptides 
with GLP-1 and insulin secretory activity. To the best of our knowledge, only three peptides (Leu-
Gly-Gly, Gly-Leu and Gly-Pro) have been reported to date which stimulate the release of GLP-1 
(Diakogiannaki et al., 2013). However, given that certain amino acids promote insulin and/or 
GLP-1 secretory activity, it is possible that short peptides containing such residues would also 
have similar effects. For example, Gly-Pro which has been shown to enhance GLP-1 release, 
forms part of the 3 amino acid repeat sequence in gelatin and, as shown in Supplementary Table 
S1 and S2, was found in abundance in peptide sequences identified in the salmon gelatin 
hydrolysate. Furthermore, this dipeptide was also found in peptide sequences identified in the 
salmon trimmings hydrolysate (Supplementary Table S3 and S4). Gln has to date been identified 
as being the most potent GLP-1 secretagogue (Reimann et al., 2004). Numerous short peptides 
containing Gln in addition to other known GLP-1 secretory residues were present in both 
hydrolysates and may contribute to the GLP-1 secretory activity observed. These peptides include 
Gln-Glu, Glu-Gln, Gln-Met, Gln-Ser, Leu-Gln, Gln-Leu, Gly-Gly-Leu-Gln, Gly-Pro-Ser-Gln, 
Gln-Pro-Pro-Glu, Gln-Glu, Glu-Gln, Gln-Ser, Phe-Gln, Ala-Leu-Gln, and Glu-Leu-Gln. 
Interestingly, peptides such as Leu-Gln, Gln-Leu, Phe-Gln, and Ala-Leu-Gln which contain 
two/three amino acids with known insulinotropic activity and peptides such as Leu-Ala, Ile-Ala, 
Ala-Leu-Leu, Ala-Leu/Ile and Leu-Leu may contribute to both insulin and GLP-1 stimulatory 














Phe-Gln, Val-Gln possess residues with known insulinotropic activity and these may have 
contributed to the insulin releasing activity observed. Furthermore, a known DPP-IV inhibitory 
peptide Gly-Pro-Ala-Gly  (Hsu, Tung, Huang, & Jao, 2013) was present in the gelatin hydrolysate, 
while the trimmings hydrolysate contained a peptide Gly-Pro-Ala-Gly-Leu containing this 
sequence. The gelatin hydrolysate derived peptides Ala-Val-Leu-Gly-Pro-Lys and Ala-Val-Leu-
Gly-Pro-Gln also contain the tetra peptide sequence Val-Leu-Gly-Pro which has previously been 
reported to exhibit DPP-IV inhibitory activity (Nongonierma & FitzGerald, 2013).  
The antidiabetic activity observed with the hydrolysate generated herein may also be due to a 
synergistic effect mediated by a combination of a number of peptides and/or amino acids and 
further research is required to identify the most potent peptide and/or amino acids responsible for 
the observed activity. 
 
3.6. In vitro antidiabetic activity of salmon co-product hydrolysates generated with Alcalase 
2.4L and Flavourzyme 500L following simulated gastrointestinal digestion (SGID) 
SGID was performed in an attempt to determine if the salmon co-product hydrolysates generated 
with Alcalase 2.4L and Flavourzyme 500L may be resistant to the enzymes that are present in the 
gastrointestinal tract of humans. The insulinotropic potential of both hydrolysates increased 
following SGID (data not shown). The salmon skin gelatin hydrolysate showed an 8.0-fold 
increase in the concentration of insulin released from BRIN-BD11 cells relative to the glucose 
control when tested at 2.5 mg/mL following SGID compared to a 3.2-fold increase prior to SGID. 
The salmon trimmings hydrolysate showed a 4.2-fold increase relative to the glucose control 
following SGID compared to a 3.0-fold increase for the hydrolysate prior to SGID. Furthermore, 
the trimmings derived hydrolysate retained GLP-1 stimulatory, (2.4- and 2.3-fold increase pre- 
and post-SGID, respectively, relative to the glucose control) and DPP-IV inhibitory (IC50 values: 














SGID. However, the gelatin hydrolysate lost its GLP-1 stimulatory activity following SGID with 
only a 0.4-fold increase in activity over the glucose control compared to a 3.2-fold increase prior 
to SGID. The DPP-IV inhibitory activity was also shown to significantly decrease (p<0.05) 
following SGID where IC50 values of 0.90 ± 0.05 and 1.19 ± 0.03 mg/mL were obtained for the 
gelatin hydrolysates pre- and post-SGID, respectively.  
An increase in the DH (16.52 to 20.58%) and the quantity of peptides < 1 kDa (67.06 to 84.21%) 
and differences in the RP-UPLC profiles (data not shown) as seen for the gelatin hydrolysate 
following SGID indicate that peptides present in the hydrolysate pre-SGID were degraded and that 
lower molecular weight peptides were generated during the SGID process. It is possible that the 
observed increase in lower molecular weight peptides mediated a more potent insulinotropic 
response, while peptides exhibiting GLP-1 secretory and DPP-IV inhibitory activity in the original 
hydrolysate were degraded during SGID. An increase in DH from 34.07 to 41.77% and peptides < 
1 kDa from 69.09 to 87.96% would indicate that further hydrolysis of the trimmings-derived 
hydrolysate took place during SGID (data not shown). However, the RP-UPLC profiles of the 
hydrolysate pre- and post-SGID were similar (data not shown). Since the GLP-1 stimulatory and 
DPP-IV inhibitory activity were retained following SGID and an improvement was seen in the 
insulin secretory activity, it is possible that peptides in the original hydrolysate mediating these 
activities were either resistant to degradation during SGID and/or additional lower molecular 
weight peptides were generated with similar or more potent activity.  
Additional small animal studies using the most appropriate diabetic animal models (for example 

















This study shows that salmon co-product-derived protein hydrolysates, in particular those 
generated using a combination of Alcalase 2.4L and Flavourzyme 500L, exhibit significant 
antidiabetic (insulin and GLP-1 secretory and DPP-IV inhibitory) activity in vitro. The specific 
biochemical pathways through which both co-product hydrolysates may mediate their 
insulinotropic activity were identified. The outcomes from SGID indicate the potential for 
translation of the activity seen in vitro to in vivo. However, investigations with diabetic animal 
models need to be performed to confirm these findings. Furthermore, the efficacy of the 
hydrolysates needs to be confirmed in human studies and the sequence of the peptides and/or 
identity of the amino acids responsible for the observed antidiabetic activity should to be 
determined. This study has identified the potential of low-value protein rich co-products, such as 
salmon trimmings and skin as rich sources of biologically active hydrolysates/peptides, which, 
following further valorisation can provide the marine industry with an opportunity to add value to 
existing salmon processing co-products. 
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Table 1. Degree of hydrolysis, molecular mass distribution and dipeptidyl peptidase (DPP)-IV 






























60.70 38.17 1.13 0 1.70 ± 0.00
b
 




 67.06 32.34 0.60 0 0.90 ± 0.05
a
 
Promod 144MG 5.77 ± 0.52
c











59.99 35.09 4.07 0.85 1.19 ± 0.00
b
 




 69.09 27.74 2.76 0.41 0.84 ± 0.04
a
 








Values represent mean ± SEM (n=3). For each co-product values with different superscript letters 




























Table 2. Total and free amino acid composition of Atlantic salmon (Salmo salar) co-product 
hydrolysates 
Amino acid Salmon skin gelatin Salmon trimmings 
Total amino acids 
(g/100 g) 
 
Free amino acids 
(g/100 g) 
 
Total amino acids 
(g/100 g) 
 
Free amino acids 
(g/100 g) 
 
Met 2.46 0.26 2.66 0.49 
Thr 2.03 0.39 3.23 0.65 
Val 1.71 0.25 3.83 0.78 
Ile 1.05 0.44 2.98 0.44 
Leu 1.75 0.40 4.97 1.17 
Phe 1.71 1.07 2.53 2.13 
His 1.33 1.10 3.88 2.55 
Lys 2.93 0.22 6.40 0.99 
Trp - nd - 0.32 
Cys 0.49 1.10 0.94 0.67 
Gly 22.60 0.88 7.07 0.22 
Tyr 0.35 1.20 1.76 1.20 
Arg 7.80 1.15 5.04 1.01 
Pro 10.63 nd 3.98 nd 
Ser 3.92 0.29 3.19 0.31 
Asx 5.72 0.03 7.31 0.30 
Glx 9.05 0.05 11.07 0.31 
Ala 7.81 0.36 5.22 0.55 
All amino acids are referred by three letter code. -: not determined, nd: not detected. Glx: Glu + 




















 Salmon co-product protein hydrolysates displayed antidiabetic activity in vitro  
 Insulin secretory activity was observed in cultured pancreatic BRIN-BD11 cells 
 Mechanisms of insulin release from pancreatic β-cells were identified 
 The salmon co-product hydrolysates enhanced GLP-1 release from GLUTag cells 
 Salmon co-product hydrolysates may have potential as antidiabetic food ingredients 
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